CTLA4 and triple-negative breast carcinoma: It has been reported that combined immunotherapy involving the use of anti-CTLA-4 monoclonal antibody and vaccine can modulate the tumor microenvironment and enhance anti-tumor immune response compared to the vaccine or monoclonal antibody alone in triple negative breast cancer (80).